Why CRISPR-Cas SDN-1 is relevant to the UPSC exam? What is the significance of topics such as Sixteenth Finance Commission, ...

The biotech has nominated MB-111, a drug it's developing as a treatment for elevated triglycerides, as its first clinical development candidate.

Glioblastoma may be driven by 3D DNA folding patterns, not just mutations, offering new paths for treatment. A new ...

Liquidia Technologies (LQDA) witnessed a jump in share price last session on above-average trading volume. The latest trend ...

From STAT’s Adam Feuerstein: The FDA informed Capricor Therapeutics that a meeting of outside experts will be convened to ...

Genetic modification process has faced criticism, with many agriculturists and scientists raising concerns over its health, ...

Developed at the Children's Hospital of Philadelphia (CHOP) and called Zynteglo, the medicine uses the patient's own stem cells to cure them.

Shares of CRISPR Therapeutics (NASDAQ:CRSP) can’t seem to catch a break, now down close to 8% year to date and more than 80% ...

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

A first-in-human clinical trial tests a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers.

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

Under the guise of "choice" and "progress" is an ideology that conceives of the human body not as sacred but as faulty ...